Enhancing Treatment Adherence with Digital Apps in the 2026 Biosimilars Sector
The digital transformation of 2026 is bringing "Connected Health" directly to the biosimilar experience through sophisticated mobile applications. For a patient managing a complex condition like multiple sclerosis, keeping track of injection sites, dates, and side effects can be a daily burden. To simplify this, many 2026 biosimilars come with a dedicated app that pairs with the medication...
0 Reacties 0 aandelen 84 Views 0 voorbeeld